ReNeuron Group PLC

Receive alerts
Market Cap:
£65.26 m
52 weeks high
52 weeks low

Viewing results 1-25 of 226


ReNeuron remains in talks with potential partners

The stem cells specialist has two active clinical trials treating patients respectively for a blindness-causing disease called retinitis pigmentosa and stroke...

1 week, 2 days ago

ReNeuron hails heavy hitting new appointments to scientific advisory board

Professor Robert MacLaren, Dr Sally Temple and Dr José-Alain Sahel have “world-class breadth of expertise” in the fields of ophthalmology and stem cell research, the company said ...

4 weeks, 1 day ago

ReNeuron inks University of Cardiff collaboration

The venture will utilise ReNeuron's exosome-based drug delivery technology...

on 14/8/19

ReNeuron granted international patents over cell technology

The stem cell specialist now has 40 patents worldwide ...

on 16/7/19

ReNeuron creates role of business development and alliance director as deals pursued

Experienced biopharma director Nick Adams “will strengthen our business development capabilities and also be a dedicated resource for managing current and future licensing agreements”...

on 12/7/19

ReNeuron enjoys “transformational” year; eye disease trial data due in October

ReNeuron’s progress over the past year has been reflected in its share price, which has trebled since last March – the beginning of the company’s financial year...

on 11/7/19

ReNeuron wins Breakthrough of the Year at 2019 Mediscience Awards

ReNeuron said it looks forward to "continuing to advance our clinical and business development activities in the months ahead"....

on 14/6/19

ReNeuron Group primed for a pivotal 18 months

The latest update reveals the company significant clinical and commercial milestones in sight ...

on 8/5/19

ReNeuron well funded for pivotal period clinically and commercially

The cell therapy specialist has two clinical trials underway and is looking at partnerships or licensing deals for its three major programmes...

on 8/5/19

ReNeuron says eye disease patients see “sustained and further improvement” after cell treatment

The company has released the latest data from a Phase IIa study of people with a blindness-causing condition called retinitis pigmentosa...

on 26/4/19

ReNeuron primed for further progress

ReNeuron Group PLC is at the forefront of stem cell science...

on 17/4/19

ReNeuron shares up 30% after it strikes deal worth up to £80mln with Chinese pharma

Fosun Pharma is licensing the rights to the company’s CTX and hRPC cell therapy programmes...

on 9/4/19

ReNeuron provides further encouraging update for potential sight-saving treatment

"We remain greatly encouraged by the continued positive efficacy we are seeing," said chief executive Olav Hellebø...

on 4/4/19

ReNeuron starts dosing second cohort in eye disease trial

The company's retinitis pigmentosa clinical programme benefits from orphan drug designation in both Europe and the US, as well as a fast track designation from the FDA in the US...

on 18/3/19

ReNeuron shares spike 20% after it provides encouraging update to Phase II eye disease trial

The first three patients in a group taking part in the Phase II portion of the study were able on average able to read an additional three lines of on the standard ETDRS eye chart after receiving treatment...

on 20/2/19

ReNeuron partner to unveil production scale-up data

Dr Nicola Goddard, of University College London, and her team have made a significant advance in the manufacture of exosomes, which are nanoparticles released by cells...

on 31/1/19

First person treated in ReNeuron’s mid-stage US stroke trial

ReNeuron has developed CTX – a stem cell therapy that it believes can help improve the quality of life for people left disabled by a stroke...

on 24/1/19